Mumbai, Oct. 23 -- Dr Reddy's Laboratories posted its results for the September quarter on Friday, with profit down 36% year-on-year to Rs.925 crore and consolidated revenue down 1.5% on-year to Rs.8,671 crore. Growth was primarily impacted by lower sales of blood cancer drug lenalidomide (Revlimid) in North America, the company said.

The underlying base business (excluding lenalidomide in North America), continued to deliver double-digit growth across businesses excluding Europe and the API business, the company said.

The company's Ebitda was Rs.1,783 crore for the quarter, with a margin of 20.6%.

Dr Reddy's had a net cash surplus of Rs.2,502 crore during the quarter.

Its largest geography, North America, reported Rs.2,489 crore in r...